1. Advances in Gastrointestinal Cancers

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Immunotherapy in Gastrointestinal Malignancies

4. dMMR and PD-1 Blockade

5. dMMR and PD-1 Blockade (cont)

6. dMMR and PD-1 Blockade (cont)

7. Immunotherapy in Hepatocellular Carcinoma

8. Nivolumab Monotherapy in HCC CheckMate-040

9. CheckMate-040 Subset Analysis

10. Pembrolizumab Monotherapy in HCC KEYNOTE-224

11. Durvalumab Monotherapy in HCC

12. Dual Checkpoint Inhibitor Therapy in HCC

13. Combined VEGF Inhibition and PD-1 Inhibition in HCC

14. Ongoing Trials and Future Directions

15. Immunotherapy in Gastroesophageal Cancer

16. Pembrolizumab Monotherapy in Gastric/Gastroesophageal Cancer

17. Nivolumab Monotherapy in Gastric and GE Junction Cancer

18. Avelumab Monotherapy in Advanced Gastric or GE Junction Cancer

19. Pembrolizumab Monotherapy in Gastric and GE Junction Cancer

20. Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Nivolumab + Ipilimumab

21. Dual Checkpoint Inhibitors in Gastric and GE Junction Cancers: Durvalumab + Tremelimumab

22. Combination VEGFR-2 and PD-1 Inhibition in the Second Line Management of Gastric or GE Junction Adenocarcinoma

23. Ongoing Trials and Future Directions

24. Immunotherapy in Pancreatic Adenocarcinoma

25. Immunotherapy in Pancreatic Cancer

26. Dual Checkpoint Inhibitors in Pancreatic Cancer

27. Chemotherapy in Combination With Checkpoint Inhibitors

28. Other Immunomodulating Agents IDO-1 Inhibitors

29. Other Immunomodulating Agents: CSF1R Blockade

30. Pancreatic Immunotherapy Ongoing trials

31. Concluding Remarks

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)